Aligos Therapeutics (ALGS) Current Deferred Revenue (2020 - 2025)

Aligos Therapeutics has reported Current Deferred Revenue for 5 years, with the latest figure at $168000.0 in Q3 2025.

• For the quarter ending Q3 2025, Current Deferred Revenue changed N/A year-over-year to $168000.0; the trailing twelve-month figure through Sep 2025 stood at $168000.0 (changed N/A YoY), and the FY2024 full-year result was $151000.0, down 88.46% from the prior year.
• Current Deferred Revenue for Q3 2025 stood at $168000.0, down from $579000.0 in the prior quarter.
• The five-year high for Current Deferred Revenue was $7.6 million in Q1 2021, with the low at $151000.0 in Q4 2024.
• Historically, Current Deferred Revenue has averaged $3.3 million across 4 years, with a median of $1.3 million in 2023.
• The largest YoY upside for Current Deferred Revenue was 88.46% in 2024 against a maximum downside of 88.46% in 2024.
• Aligos Therapeutics' Current Deferred Revenue stood at $6.6 million in 2021, then sank by 80.29% to $1.3 million in 2023, then sank by 88.46% to $151000.0 in 2024, then advanced by 11.26% to $168000.0 in 2025.
• The last three Current Deferred Revenue figures came in at $168000.0 (Q3 2025), $579000.0 (Q2 2025), and $151000.0 (Q4 2024), per Business Quant data.